Biotech Company With Clinical Operations Developing Psychedelic Medicine To Treat Addiction

First 3 UK Clinics Opened In 2021, Targeting 20 Clinics By 2024 ~$100M In Revenue

Free
Message: AGORACOM Small Cap 60: Awakn Phase II Trial For AUD Exceeds Company Expectations

Share
New Message
Please login to post a reply